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Goals: The aim of this study was to validate the ability of symptom
frequency questionnaire to differentiate between irritable bowel
syndrome (IBS) patients and healthy subjects.
Background: A digestive symptom frequency questionnaire
(DSFQ) was previously used in a food efficacy trial in a non-IBS
population with mild gastrointestinal symptoms.
Study: We compared 2 well-defined populations: 100 IBS patients
fulfilling Rome III criteria (mean age 32 y; range, 18 to 59 y), and
100 sex-matched and age-matched healthy subjects. Frequency of
individual digestive symptoms (abdominal pain/discomfort, bloat-
ing, flatulence, borborygmi) was assessed using a 5-point Likert
scale (from none to everyday of the week) and the IBS severity
with the IBS-SSS questionnaire. Health-Related Quality of life
(HRQoL) was assessed with the Food and Benefits Assessment
(FBA) and Functional Digestive Disorders Quality of Life
(FDDQL) questionnaires. The digestive (dis)comfort dimension of
these questionnaires was considered as the main dimension for
HRQoL.
Results: The DSFQ discriminated IBS from healthy subjects with a
significant difference (P<0.001) between groups (estimated mean
difference=5.58; 95% CI, 4.91-6.28). On the basis of the ROC
curve (AUC=0.9479), a cutoff value of 5 gives a sensitivity of
92% and a specificity of 84%, with a positive likelihood ratio of
5.75. Composite score of symptoms correlated strongly
(P<0.0001) with digestive discomfort measured by FDDQL
(0.816), digestive comfort measured by FBA (0.789), and the
IBS-SSS score (0.762).
Conclusions: Measurement of digestive symptom frequency by
means of the DSFQ can differentiate IBS from healthy subjects,
and shows a good correlation with other validated questionnaires
(clinical trial #NCT01457378).
Key Words: digestive symptoms, patient-reported outcome, irrita-
ble bowel syndrome, quality of life
(J Clin Gastroenterol 2015;49:e64–e70)
Digestive symptoms are very common complaints in thegeneral population.1,2 The type, frequency, and inten-
sity of these symptoms largely vary between subjects3–5 and
may impact their daily life.2,6 Abdominal pain/discomfort
and bloating are often reported as the more troublesome
and frequent symptoms, especially in irritable bowel syn-
drome (IBS).7,8 In the absence of validated biomarkers
allowing objective measures of these symptoms, patient-
reported outcomes (PRO) are recognized as valuable
instruments to measure patients’ perception of symptoms.
Such instruments are therefore used in clinical trials to
determine the efficacy of food or drugs in alleviating
digestive symptoms.9–11 Owing to the interindividual vari-
ability in intensity, severity, and fluctuation over the time,
appropriate PRO should be used according to the target
population.
Measures of digestive symptoms are available for spe-
cific functional gastrointestinal (GI) disease, but there is a
lack of questionnaires for the general population. Most
symptom questionnaires have been developed to be used in
IBS and mainly focused on symptom severity. Severity of
individual digestive symptoms has been measured in differ-
ent ways, including 5-point Likert scale (from none to very
severe) or 21-, 11-, or 10-point numeric scales, on a daily or
weekly basis.12 Overall severity of IBS has been measured
with a questionnaire (IBS-SSS) scoring different aspects of
the disease (pain, bloating, bowel dysfunction, and quality of
life).13 Despite its use in populations of patients with IBS,
there are no data in the literature supporting the use of these
questionnaires in the general population. Indeed, those
PROs may lack sensitivity to detect changes in the general
population reporting occasional digestive symptoms or even
in the very mild spectrum of IBS.
To measure the efficacy of dietary intervention on
digestive symptoms in the general population, a simple
PRO was developed. This PRO assessed the frequency over
a 1-week period of 4 digestive symptoms (abdominal pain/
discomfort, bloating, flatulence, and rumbling stomach/
borborygmi) using 5-point Likert scales (from none to
everyday of the week).14 This digestive symptom frequency
questionnaire (DSFQ) proved to be sensitive to detect sig-
nificant changes in response to a probiotic compared with
control food product in 2 independent interventional
studies in the general population reporting mild GI
discomfort.14,15
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Our current aim was to determine the sensitivity and
specificity of this questionnaire to differentiate healthy
subjects and IBS patients, to compare it with a validated
severity questionnaire in IBS subjects (IBS-SSS), and to
correlate the frequency of digestive symptoms with Health-




Patients with IBS (n=100; 18 y and above), meeting
Rome III criteria (all subtypes),5 and 100 age-matched (18
to 35, 36 to 50, and 51 to 65 y) and sex-matched healthy
control (HC) subjects were included in the study. Partic-
ipants were recruited by public advertisement and from the
database of 2 clinical centers in France (Eurofins Optimed,
Gières; and RPS France, Caen). Diagnosis of IBS was
established using the Rome III questionnaire.5 Patients
were required to have a score of >75 on the IBS-SSS at the
time of the study (active disease). Patients were excluded if
they had clinical signs of alarm (eg, rectorragy, fever, recent
weight loss), a known organic disease, including inflam-
matory bowel disease or cancer, or if they were on anti-
depressant or analgesic drugs. Healthy subjects were
excluded if they had consulted a general practitioner or a
gastroenterologist for any functional bowel disorder, had a
known organic disease, or received any chronic medical
treatment that could influence the GI tract. Healthy sub-
jects completed the Rome III questionnaire to confirm the
absence of any functional bowel disorder.
Ancillary Study
In addition, a larger cohort of subjects (521 women,
age 18 to 60 y), who had participated in 2 previous inde-
pendent randomized controlled trials using the same ques-
tionnaires, were analyzed to assess the stability of the
questionnaire14,15; these subjects recruited from the general
population reported minor GI discomfort, defined by the
presence of mild digestive symptoms (ie, abdominal dis-
comfort/pain, bloating, flatulence/passage of gas, borbor-
ygmi/rumbling stomach) in the past month, but did not
fulfill the criteria of functional digestive disorders.
The study protocol was approved by the Ethics
Committee Sud Est III (Lyon, France). All participants
gave written informed consent before inclusion in the study.
The study is registered at Clinicaltrials.gov: NCT 01457378.
Study Design and Procedures
Main Study
A multicenter, observational, prospective study was
conducted in France with a single visit for all participants.
During the visit, all participants [patients with IBS
(n=100) and 100 age-matched and sex-matched HC sub-
jects] were instructed to fill out 4 questionnaires: the DSFQ
(frequency of digestive symptom), IBS-SSS (severity of IBS
symptoms), Food and Benefits Assessment (FBA) ques-
tionnaire (HRQoL), and Functional Digestive Disorders
Quality of Life (FDDQL) questionnaire (HRQoL). The
recall period was 7 days for DSFQ questionnaire, 10 days
for the IBS-SSS, and 2 weeks for both FDDQL and FBA
questionnaires.
Ancillary Study: Stability of the Questionnaire
Retrospective study reanalyzing data of participants in
2 previous studies who had filled out the questionnaire 2
times 1 week apart during baseline before intervention.
Frequency of Digestive Symptoms (DSFQ)
The frequency of 4 digestive symptoms (abdominal
pain/discomfort, bloating, flatulence/passage of gas, and
borborygmi/rumbling stomach) was evaluated using the
DSFQ. The frequency of each digestive symptom over a 1-
week period was assessed with a 5-point Likert scale [never
(0); 1 time per week (1); 2 to 3 days per week (2); 4 to 6 days
per week (3); everyday during the week (4)]. A composite
score was calculated corresponding to the sum of the scores
of the 4 individual symptoms, leading to a score ranging
from 0 (never=0 for the 4 symptoms) to 16 (everyday of
the week=4 for the 4 symptoms).14
IBS Symptom Severity Scale (IBS-SSS)
IBS severity was assessed using the validated IBS-SSS
questionnaire.13 This symptom questionnaire contains 5
questions scoring abdominal pain (2 questions), abdominal
distension/bloating, satisfaction with bowel habit, and
impact of IBS on patients’ life. All 5 questions contribute
equally to a score from 0 to 500. This questionnaire
established 3 IBS severity classes: mild (score 75 to 174),
moderate (score 175 to 299), or severe (300 to 500). Scores
<75 indicate normal bowel function or IBS subjects in
inactive period.
HRQoL (FBA and FDDQL)
HRQoL of subjects was assessed by self-admin-
istration of the FBA16 and the FDDQL17 questionnaires.
The FBA questionnaire assessed the impact of diet and
nutrition on HRQoL. The FBA questionnaire comprises 41
items scoring 7 dimensions (snacking, vitality, well-being,
physical appearance, esthetics, digestive comfort, and dis-
ease prevention). The scores range from 0 (worst) to 100
(best possible).
The FDDQL questionnaire assesses the impact of
digestive complaints on HRQoL. This measure comprises
43 items scoring 8 dimensions (daily activities, anxiety, diet,
sleep, health perception, digestive discomfort, coping with
disease, and impact of stress). An algorithm provides a
complete score for each dimension ranging from 0 (worst)
to 100 (best possible).
Statistical Analyses
The sample size of this study had to capture appro-
priately the variability induced by the pattern of the pop-
ulation (IBS and HC subject), and to allow the exploration
of all the range of the questionnaires. This consideration
taken into account and the exploratory nature of the study
led to state the sample size to 200 completed subjects (100
IBS subjects and 100 HC subjects). With a single evaluation
visit, no dropouts were expected, and 200 subjects had to be
included.
For this study, all the analyses were performed on the
Full Analysis Set population that corresponds to all
the subjects screened and included in the study (ie, all the
eligible subjects).
To compare the composite score between IBS and HC
subjects, the quantitative composite score was analyzed using
a variance analysis with subject status (IBS vs. HC) and the
stratification covariates (age and sex) as explicative factors.
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Regardless of the significance, all variables were kept in the
model. Adjusted means values of composite score were
computed. The underlying assumption of the normality of
residuals was checked according to Skewness and Kurtosis
indicators as to which values should be in range of 1.5
to 1.5.
To determine with more accuracy whether the com-
posite score is a good tool for discriminating IBS from HC
subjects, a receiver operating characteristic (ROC) built to
assess the prediction of the subject status according to the
composite score was computed. The value of the area under
the ROC was calculated, and this ROC curve enabled to
choose a reliable threshold to transform the composite
score into a binary variable. The threshold was chosen
upstream of other analyses to guarantee the integrity of the
decision. This threshold of definition of binary composite
score variable was chosen in favor of the discrimination of
the rate of “true” IBS subjects, thus basing it on the best
sensitivity. On the basis of this threshold, the sensitivity and
specificity were calculated according to (i) and (ii).
Sensitivity ¼
Number of true positives
Number of true positivesþ number of false negatives
ðiÞ
Specificity ¼
Number of true negatives
Number of true negativesþnumber of false positives
ðiiÞ
Then according to (iii) and (iv) likelihood ratios (LR) were
calculated. LRs summarize the information contained in
both sensitivity and specificity, a highlight on how likely a
given test result is in people with the condition, compared
with how likely it is in people without the condition.








The higher the positive LR, the more likely a com-
posite score Z5 predicted an IBS subject as IBS; the lower
the negative LR, the more likely a composite score <5
predicted a healthy subject as healthy; a LR close to 1
means that the composite score is not predictive of the
subjects’ status (IBS or HC).
To study the relationship between the composite score
and IBS-SSS, a logistic regression was performed with the
binary composite score as a response variable and with IBS-
SSS modalities and age/sex stratification as explicative
variables. Regardless of the significance, all variables were
kept in the model. To study the relationship between the
composite score and digestive (dis)comfort of HRQoL
questionnaires, correlations were computed and assessed
with the Spearman rank correlation coefficient.
Effect sizes were used to better understand the rela-
tionship between the frequency of the digestive symptoms
(through the composite score) and the variation of HRQoL
questionnaire dimensions (all dimensions of FBA and
FDDQL questionnaires), without the subjects’ status
dimension. Four modalities of the composite score were
defined according to the quartiles, with the first quartile as
the reference modality.
To evaluate possible relationships between the diges-
tive symptoms and HRQoL questionnaires, a Canonical
Correlation Analysis was performed. Results are presented
with a relevance network computing similarity values
between each variable, representing the composite score of
the digestive symptoms and HRQoL questionnaires. The
closer the similarity value is to 1 (or 1), the better the
association is (positive for +1 and negative for 1). The
closer this similarity value is to 0, the worse the association
is. The relevance network with similarity values >0.5 was
considered as a relevant association.
Reproducibility of the questionnaire (stability over
time), in the ancillary study, was measured by the intraclass
correlation coefficient (ICC) between 2 consecutive assess-
ments 1 week apart during the baseline period of 2
randomized controlled trials. During this period, subjects
are considered in stable healthy status.
Statistical analyses were performed using SAS Soft-




IBS patients and HC subjects were comparable for age
and BMI (Table 1). The population was female predom-
inant (78%). The severity of IBS was mainly moderate
(63%) and IBS subtypes were well represented in the sam-
ple. All HC subjects reported normal bowel as measured by
IBS-SSS (scores <75).
Discrimination of IBS Patients From Healthy
Subjects
As expected, IBS patients had higher composite and
individual digestive symptoms scores than HC subjects
(Table 2). Flatulence was the more frequent symptom in
both groups. IBS-C exhibited the highest composite score
among IBS subtypes. The composite score significantly
discriminated between IBS and healthy subjects (P<0.001
significance between group and estimated mean differ-
ence=5.58; 95% CI, 4.91-6.28), with no impact of sex or
age. Receiver-operating curve analysis comparing all IBS
patients with HC subjects (Fig. 1) gave a ROC score of
0.95. The choice of the cutoff value was based on 3 points
on the curve corresponding to the range 4 to 6 of the
composite score. Among these 3 points, the sensitivity
varied from 95% to 83% and specificity varied from 76%
TABLE 1. Demographics in Healthy Control (n = 100) and IBS
Patients (n = 100)
Variable HC (n=100) IBS (n=100)
Age (range) (y) 39.2±13.6 (18-65) 40.7±13.3 (18-65)
BMI (range)
(kg/m2)




IBS subtype* — C: 31%; D: 29%;
M: 40%
IBS severityw No: 100% No: 0%; Mi: 16%;
Mo: 63%; S: 21%
Age and BMI are expressed as mean±SD with range.
*IBS subtype was determined with Rome III classification: C, con-
stipated; D, diarrhea; M, mixed or unsubtyped.
wIBS severity was assessed with the IBS-SSS: No=normal bowel
function or IBS in inactive period (0-74); Mi, mild, score (75-174): Mo,
moderate, score (175-299); S, severe, score (300-500).
BMI indicates body mass index; HC, healthy control; IBS, irritable
bowel syndrome.
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to 92%. A cutoff of >5 was chosen to obtain the best
sensitivity for discriminating IBS patients fulfilling Rome
III criteria from subjects in the general population, with
92% sensitivity and 84% specificity, and a positive LR of
5.75 and a negative LR of 0.17.
Receiver-operating curves comparing all IBS patients
with HC subjects were also performed using the digestive
(dis)comfort dimension scores of FBA and FDDQL
questionnaires. ROC scores were also excellent for
both questionnaires: 0.98 and 0.95 for FDDQL and FBA,
respectively. The cutoff values of 72.22 and 69.44 were
retained for FDQQL and FBA, respectively. The associated
sensitivity and specificity were: 98% and 94% for FDDQL;
91% and 87% for FBA.
Relationship Between Composite Score of
Digestive Symptoms and IBS-SSS and Digestive
(Dis)Comfort of HRQoL Questionnaires
IBS patients had significantly lower score of both
digestive comfort dimension of FBA questionnaire and
digestive discomfort FDDQL questionnaires than healthy
subjects (Table 3). A significant correlation (Spearman
coefficient=0.762, P<0.001) between the composite score
of the DSFQ and IBS-SSS score was observed (Table 3).
The composite score of the DSFQ negatively correlated
(P<0.001) with these 2 HRQoL dimensions (Table 3).
Logistic regression modeling of the probability that
the composite score of digestive symptoms frequency is
superior to the cutoff of 5 according to IBS-SSS modalities
showed that IBS classes (normal, mild, moderate, severe)
were statistically significantly (P<0.001) with a gradient
of odd ratios with the severity of IBS (Table 4).
Relationship Between Digestive Symptoms and
HRQoL Questionnaires
The scores for all the dimensions of both ques-
tionnaires were lower in IBS patients than in healthy
subjects (Table 5). Effect size calculation was used to
investigate the relationship between the increase in com-
posite score of digestive symptoms and worsening of
HRQoL corresponding to decreased scores of dimensions
of FBA and FDDQL questionnaires (Figs. 2, 3). Effect size
value increased with composite score for all dimensions of
FBA and FDDQL, except for FBA disease prevention and
FDDQL impact of stress and health perception. For FBA
questionnaire, higher gradient was observed for digestive
comfort with effect size ranging from 1.23 to 3.52,
whereas the effect size for other dimensions was mainly
<0.8. For FDDQL, most of the dimensions (anxiety,
coping with disease, daily activities, diet, digestive dis-
comfort, sleep) showed a relevant gradient, with an effect
size >0.8 for the 2 groups with higher composite score. The
digestive discomfort dimension showed the larger effect size
ranging from 0.82 to 4.21.
Canonical Correlation Analysis was performed to
assess the network of associations between individual
digestive symptom and HRQoL dimensions. Digestive
comfort of FBA and digestive discomfort of FDDQL were
the only 2 dimensions associated with the 4 digestive
symptoms. Higher associations were observed for
abdominal pain and bloating for FBA digestive comfort
(0.75 for both symptoms) and FDDQL digestive dis-
comfort (0.87 and 0.90, respectively). These 2 symp-
toms were also associated with 4 other dimensions of
FDDQL (daily activities, sleep, anxiety, and diet). PCA
also showed that abdominal pain and bloating were highly
correlated.
Stability of the Measure
The reproducibility of the measure was tested with
baseline data corresponding to readministration of the
TABLE 2. Composite Score of Digestive Symptoms, and Individual Digestive Symptoms Scores in Healthy Controls (n = 100) and IBS
Patients (n = 100)
Variable HC (n=100) IBS (n=100) IBS-C (n=31) IBS-D (n=29) IBS-U/M (n=40)
Composite score 2.4±2.0 (2.0-2.8) 7.9±2.7 (7.4-8.5) 8.5±3.1 (7.4-9.7) 7.1±2.7 (6.1-8.1) 8.1±2.3 (7.3-8.8)
Abdominal pain 0.1±0.2 (0.0-0.1) 1.8±0.9 (1.6-2.0) 2.1±1.0 (1.7-2.4) 1.6±0.9 (1.2-1.9) 1.7±0.6 (1.5-1.9)
Bloating 0.2±0.4 (0.1-0.3) 2.1±0.9 (1.9-2.2) 2.4±1.0 (2.1-2.8) 1.7±0.9 (1.4-2.1) 2.0±0.7 (1.8-2.2)
Flatulence 1.4±1.3 (1.1-1.6) 2.3±1.1 (2.1-2.5) 2.3±1.1 (1.9-2.7) 2.0±0.9 (1.7-2.4) 2.5±1.1 (2.1-2.8)
Borborygmi 0.7±1.0 (0.5-0.9) 1.8±1.0 (1.6-2.0) 1.7±1.1 (1.3-2.1) 1.8±1.0 (1.4-2.1) 1.9±1.0 (1.6-2.2)
Values are mean±SD (95% CI).
CI indicates confidence interval; HC, healthy control; IBS, irritable bowel syndrome.
FIGURE 1. Receiver-operating curve (ROC) for distinguishing IBS
(n = 100) from HC (n = 100) using composite score of digestive
symptoms. Sensitivity versus 1specificity is given for different
cutoff values. The area under the curve was 0.95. HC indicates
healthy control; IBS, irritable bowel syndrome.
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questionnaire 1 week apart (Table 6). The ICCs for indi-
vidual digestive symptoms and for composite score range
from 0.64 to 0.83, suggesting good stability.
DISCUSSION
Our data show that the sensitivity and specificity of the
composite score of the 4 digestive symptoms measured by
the DSFQ are good, as shown by the ROC curve analysis,
in discriminating 2 well-defined groups of healthy subjects
and IBS patients. This composite score correlated well with
different validated PROs, including a severity questionnaire
in IBS (IBS-SSS),13 and with the digestive (dis)comfort of 2
HRQoL questionnaires (FDDQL and FBA).16,17 These
data support the validity and robustness of this symptom
questionnaire.
Development of new valid and reliable PROs meas-
uring digestive symptoms in clinical trials is an important
area of research. For example, no fully validated PRO,
meeting the requirement of drug agencies, is available to
date for IBS drug trials, and partially validated PRO, such
as 11-point numeric rating scale for abdominal pain,18 is
therefore judged as acceptable study outcome by both FDA
and EMA.10,11 Most of these research studies have focused
on IBS or other types of functional GI disorders, whereas
few initiatives have been taken in the general population
without functional GI disorders. This population is the
target for claims on the reduction of digestive discomfort
for many foods (eg, fiber, probiotics) both in Europe and
the United States. However, more studies are recommended
in this general healthy population to provide adequate
scientific evidence to support such claims.19 The develop-
ment of simple and reliable PRO for measuring digestive
symptoms in this population should be useful in this
perspective.
This symptom questionnaire distinguished a well-
characterized group of IBS patients from healthy subjects
as demonstrated by the high ROC score (0.95). Using a
cutoff of >5, the sensitivity of this instrument to identify
IBS is very high (92%), with a very good specificity (84%).
These results are comparable to those obtained with the
digestive discomfort dimension of the FDDQL ques-
tionnaire (sensitivity: 98%; specificity: 91%), which was
specifically developed in patients with functional bowel
disorders including IBS.17 With a similar level of sensitivity
and specificity, the symptom frequency questionnaire is
simpler, quicker, and easier to apply than FDQL. The
reliability of this new instrument was good, with an
ICC>0.70.20 The individual symptoms also showed a
good (>0.7 for flatulence, bloating, and borborygmi) or
acceptable reliability (>0.6 for abdominal pain). The
Gastrointestinal Symptom Rating Scale, one of the most
established, reliable, and responsive disease-specific PROs
in functional bowel disorders, has been shown to exhibit
lower low test-retest reliability ranging from 0.42 to 0.69
according to dimension.21,22
The symptom questionnaire was also tested against
validated IBS severity questionnaire and digestive (dis)-
comfort dimension of HRQoL questionnaire. The compo-
site score of the DSFQ significantly correlated with these 3
validated PROs. This supports the idea that symptom
frequency is moving in the same direction of other mean-
ingful measures. The increase in the severity of IBS as
measured by IBS-SSS is clearly associated with an increase
in the composite score that seems independent from the IBS
subtype. Regarding the 2 HRQoL questionnaires, larger
TABLE 4. Relationship Between Composite Score of Digestive Symptoms Frequency and Severity of IBS
IBS Severity Classes
Variable Normal (n=100) Mild (n=16) Moderate (n=63) Severe (n=21)
Composite score digestive symptoms* 2.4±2.0 (2.0-2.8) 6.4±2.3 (5.2-7.7) 7.6±2.3 (7.0-8.1) 10.2±3.0 (8.9-11.6)
Class 0 to 5w 84 (84) 3 (18.7) 4 (6.3) 1 (4.8)
Class 5 to 8w 15 (15) 7 (43.8) 27 (42.9) 2 (9.5)
Class 8 to 16w 1 (1) 6 (37.5) 32 (50.8) 18 (85.7)
Logistic regressionz — 28.1 (6.6-119.1) 96.3 (28.5-325.0) 129.7 (15.4-1091.5)
*Value for each class of IBS-SSS is expressed as mean±SD with 95% CI in brackets.
wProportion of subjects in each class of composite score of digestive symptoms is given in number and percentage in brackets.
zLogistic regression was used to estimate the probability that composite score is 5 to 16 for mild, moderate, and severe class of IBS versus normal group.
Results are expressed as odds ratio with 95% CI in brackets. All results were statistically significant (P<0.001).
CI indicates confidence interval; IBS, irritable bowel syndrome.
TABLE 3. Correlations Between Composite Score of Digestive Symptoms Frequency and Other Measures
Variable IBS (n=100)* HC (n=100)*
Correlation With Digestive
Composite Scorew
IBS-SSS 242.0±72.1 (227.6-256.3) 12.2±10.5 (10.1-14.2) 0.762***
Digestive comfort FBA 83.8±12.7 (81.3-86.3) 50.7±14.1 (47.9-53.5) 0.789***
Digestive discomfort FDDQL 90.2±9.5 (88.3-92.1) 47.3±14.5 (44.4-50.1) 0.816***
*Values are mean±SD (95% CI).
wCorrelations values are Spearman rank correlation coefficient.
***Significant correlation, P<0.0001.
CI indicates confidence interval; HC, healthy control; IBS, irritable bowel syndrome.
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effect sizes (up to 3 to 4) were observed for digestive dis-
comfort (FDDQL) and digestive comfort (FBA). Analysis
of the network of associations between HRQoL dimensions
and the symptoms showed that the 4 symptoms assessed
with the composite score were all associated with these 2
dimensions measuring digestive comfort concept. Other
HRQoL dimensions were less associated with composite
score, anxiety, daily activities, diet dimensions of FDDQL,
and, in a lesser extent, vitality and well-being dimensions
of the FBA being the more impacted by changes in
composite score. In addition, this symptom frequency
questionnaire was also shown to be associated with changes
(improvement and worsening) in GI well-being in a general
population of subjects reporting mild digestive symptoms.23
Another important aspect to consider when evaluating
a digestive symptom questionnaire is its ability to detect
changes in efficacy clinical trials. This instrument was pre-
viously used in 2 independent double-blind controlled
clinical trials in women reporting mild digestive symptoms
testing the ability of a probiotic food to improve digestive
comfort.14,15 Significant decreases in both trials were
observed supporting the ability of this PRO to detect
changes between treatment groups. However, this PRO was
never tested in an IBS trial yet. Interestingly, in these 2
clinical trials, participants with mild digestive symptoms
but not fulfilling the criteria of IBS had baseline composite
scores (mean score around 7) within the range of mild-to-
moderate IBS observed in the present study. This may
suggest a continuum in digestive symptoms from normal
digestive sensations to severe digestive complaints. Such
continuum has been described in human physiology such as
blood pressure.24 This opens the possibility to investigate
continuum in terms of frequency of digestive symptoms
between different types of apparently different populations
reporting mild-to-moderate digestive symptoms. This could
help in better characterizing study population in future
clinical trials and to select homogenous group of
TABLE 6. Stability of the Frequency Digestive Symptom
Questionnaire
Abdominal
Pain Flatulence Bloating Borborygmi
Composite
Score
ICC 0.64 0.83 0.74 0.77 0.78
Intraclass correlation coefficients (ICC)>0.7 represent good reliability;
values >0.6 represent acceptable reliability.
FIGURE 2. Effect size of FBA questionnaire dimensions according
to composite score of digestive symptoms (FAS population,
n = 200). Results are expressed as effect size for each class (2 to 5;
5 to 8; 8 to 16) for each dimension of the FBA questionnaire. The
reference group used for effect size estimation is the group with
the lowest composite score scores (0 to 2). Effect sizes of 0.5 and
0.8 are typically considered moderate and large between-group
differences, respectively. FAS indicates Full Analysis Set; FBA,
Food and Benefits Assessment.
TABLE 5. Scores of the Dimensions of FBA and FDDQL
Questionnaires in HC Subjects and IBS Patients
Variable HC (n=100) IBS (n=100)
FBA questionnaire
Esthetics 75.1±15.5 (72.0-78.2) 65.7±15.4 (62.6-68.7)
Disease
prevention
80.3±18.0 (76.7-83.9) 79.3±17.6 (75.8-82.8)
Physical
appearance
70.3±24.7 (65.4-75.1) 49.3±20.7 (45.2-53.3)
Snacking 62.0±20.4 (58.0-66.0) 52.5±23.0 (47.9-57.1)
Vitality 76.2±12.0 (73.8-78.5) 63.0±14.1 (60.2-65.8)
Well-being 75.0±17.7 (71.4-78.5) 59.3±17.3 (55.9-62.8)
FDDQL questionnaire
Anxiety 98.0±4.2 (97.2-98.9) 66.2±20.6 (62.1-70.3)
Coping with
disease
71.3±22.4 (66.9-75.8) 47.0±23.3 (42.4-51.6)
Daily activities 97.9±3.8 (97.2-98.7) 79.0±15.9 (75.9- 82.2)
Diet 91.2±11.0 (89.1-93.4) 62.5±17.7 (59.0-66.0)
Health
perceptions
79.3±15.3 (76.3-82.3) 69.4±16.1 (66.2-72.6)
Impact of
stress
62.5±28.6 (56.8-68.2) 44.5±26.6 (39.2-49.8)
Sleep 94.6±11.4 (92.3-96.9) 67.3±20.3 (63.3-71.4)
Values for each dimension are expressed as mean±SD with 95% CI in
brackets.
CI indicates confidence interval; FBA, Food and Benefits Assessment;
FDDQL, Functional Digestive Disorders Quality of Life; HC, healthy
control; IBS, irritable bowel syndrome.
FIGURE 3. Effect size of FDDQL questionnaire dimensions
according to composite score of digestive symptoms (FAS pop-
ulation, n = 200). Results are expressed as effect size for each class
(2 to 5; 5 to 8; 8 to 16) for each dimension of the FBA ques-
tionnaire. The reference group used for effect size estimation is
the group with the lowest composite score scores (0 to 2). Effect
sizes of 0.5 and 0.8 are typically considered moderate and large
between-group differences, respectively. FAS indicates Full
Analysis Set; FBA, Food and Benefits Assessment; FDDQL, Func-
tional Digestive Disorders Quality of Life.
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participants regarding symptoms frequency. Such a simple
and easy to administer instrument could be a useful tool in
large population survey, looking at the prevalence of
digestive symptoms in different sets of population (general
population, patients with functional GI disorders).
A potential limitation of our questionnaire is that it
captures only 1 dimension, that is, frequency of the digestive
symptoms, and in the more severe spectrum of IBS, the
intensity, the bothersomeness, and the interference of the
symptoms with daily activities may be important.25 This may
mask differences between patient groups; however, the pres-
ent data showed the ability of this PRO to detect differences
between IBS patients with different degrees of disease
severity. Another point to consider when using this PRO is
the contribution of each symptom to the composite score that
may vary between subjects. This should be of importance
according to the research question addressed, that is, looking
at overall symptoms pattern or at specific individual symp-
toms. Further investigations are required to better determine
how this questionnaire could be used in IBS clinical trials.
Frequency might be a better indicator of digestive symptoms
in the general healthy population compared with severity or
intensity. Owing to the low severity/intensity of digestive
symptoms in this nondisease population, PROs measuring
this aspect of the symptoms are likely to not be enough
sensitive to capture changes because of floor effect.
In conclusion, the findings of this study support the
validity of the DSFQ assessing the frequency of 4 digestive
symptoms (abdominal pain, bloating, flatulence, and bor-
borygmi/rumbling stomach). This instrument is a simple
quantitative questionnaire test by which clinical responses
to therapeutic trials or variation of functional digestive
symptom over time may be evaluated in clinical settings.
The questionnaire may be a particularly useful tool for the
evaluation of symptoms in the general population, and in
patients with mild-to-moderate complaints not fulfilling the
criteria of functional GI disorders, and in this context the
questionnaire covers a heretofore unmet need.
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